Genus (GNS) Share Price, News & Analysis

Company Overview

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.

Key Stats

• Today's Range: 2,540 to 2,640
• 50-Day Range: 2,290 to 2,760
• 52-Week Range: 1,424 to 3,228.80
• Volume: 1.47 million shs
• Average Volume: 257,397 shs
• Market Capitalization: £1.68 billion
• P/E Ratio: 8,806.23
• Dividend Yield: 0.01%
• Price Target: GBX 2,900
• Consensus Rating: Buy

Genus Stock Analysis - MarketRank™

Genus scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Buy

Consensus Rating

Genus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Genus has a consensus price target of GBX 2,900, representing about 13.9% upside from its current price of GBX 2,545.

Amount of Analyst Coverage

Genus has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Genus is 8,806.23, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 230.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genus is 8,806.23, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 85.27.

Price to Earnings Growth Ratio

Genus has a PEG Ratio of 2.87. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Genus has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GNS.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Genus pays a meaningful dividend of 1.21%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Genus does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Genus is 110.73%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GNS.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Genus has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Genus this week, compared to 1 article on an average week.

Search Interest

14 people have searched for GNS on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genus insiders have sold more of their company's stock than they have bought. Specifically, they have bought GBX 0 in company stock and sold £80,454 in company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Genus is held by insiders.

Percentage Held by Institutions

63.38% of the stock of Genus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GNS Stock Analysis - Frequently Asked Questions

How have GNS shares performed this year?

Genus' stock was trading at GBX 1,550 at the beginning of 2025. Since then, GNS shares have increased by 64.2% and is now trading at GBX 2,545.

How were Genus' earnings last quarter?

Genus plc (LON:GNS) announced its quarterly earnings results on Thursday, September, 4th. The company reported $81.80 EPS for the quarter. Genus had a net margin of 1.18% and a trailing twelve-month return on equity of 1.41%.
Read the conference call transcript.

How do I buy shares of Genus?

Shares of GNS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Genus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genus investors own include Meta Platforms (META), Lloyds Banking Group (LLOY), Rolls-Royce Holdings plc (RR.L), AstraZeneca (AZN), Barclays (BARC), BP (BP) and Clinigen Group (CLIN).

Company Calendar

• Last Earnings: 9/04/2025
• Today: 10/10/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Personal Services
• Current Symbol: LON:GNS
• CIK: N/A
• Web: www.genusplc.com
• Phone: +44-1256-347100
• Fax: N/A
• Employees: 480
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Genus: GBX 2,900
• High Price Target: GBX 2,900
• Low Price Target: GBX 2,900
• Potential Upside/Downside: +13.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 0.29
• Trailing P/E Ratio: 8,806.23
• Forward P/E Ratio: 35.86
• P/E Growth: 2.87
• Net Income: £7.87 million
• Net Margins: 1.18%
• Pretax Margin: N/A
• Return on Equity: 1.41%
• Return on Assets: 3.31%

Debt

• Debt-to-Equity Ratio: 53.12
• Current Ratio: 1.80
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: £672.80 million
• Price / Sales: 2.50
• Cash Flow: GBX 50.33 per share
• Price / Cash Flow: 50.56
• Book Value: GBX 827.95 per share
• Price / Book: 3.07

Miscellaneous

• Outstanding Shares: 66,193,000
• Free Float: N/A
• Market Cap: £1.68 billion
• Optionable: Not Optionable
• Beta: 0.37